The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00853476

Enrollment

Registered

2009-03-02

Start date

2009-03-31

Completion date

2009-10-31

Last updated

2011-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intradermal Test

Brief summary

This study aims to compare skin reactivity results between morphine and histamine as a positive control agents in intradermal skin test.

Detailed description

Histamine hydrochloride and different concentrations of morphine sulfate will be intradermally injected and wheal diameter size will be comparatively measured between 15-30 minutes' time points after the test.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* age 18-60 years old

Exclusion criteria

* immunodeficiency state * cancer * severe skin diseases * severe medical illnesses * malnutrition * uncontrolled asthma * pregnancy * received oral or systemic corticosteroid within 1 month before this study * receiving immunosuppressive agents * taken antihistamine within 3 days before this study * taking beta-blocker * previous history of immunotherapy * have hypersensitivity reaction to morphine/opiates

Design outcomes

Primary

Measure	Time frame
Wheal diameter from morphine skin test at different concentrations compared to standard histamine between 15-30 minutes after skin test	30 minutes

Secondary

Measure	Time frame
Side effects	24 hours

Countries

Thailand

Outcome results